Business Wire

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar

Share

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab).

Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea.

Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year.

FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and separately from this procedure, it has confirmed the resumption of the review procedure for the two proposed biosimilars upon the resubmission of the aBLAs.

Celltrion and Teva Pharmaceutical Industries, Ltd. entered into an exclusive partnership to commercialize CT-P10 and CT-P6 in the U.S. and Canada in October 2016. As part of the agreement, Teva is responsible for all commercial activities in the U.S. and Canada, pending regulatory approvals for both products. Celltrion is responsible for completing all clinical developments and regulatory activities.

About CT-P6

The reference product for CT-P6 is Herceptin® (trastuzumab)1. Herceptin® is used to treat cancer patients whose tumors have either HER2 overexpression or HER2 gene amplification. Similarity of CT-P6 to the reference product, Herceptin®, was demonstrated in terms of pharmacokinetic, pharmacodynamics, efficacy and safety through multiple global clinical trials. CT-P6 is currently pending FDA review and approval. The final U.S. prescribing information for CT-P6 will include the specific uses for which the product is indicated in the U.S. CT-P6 was approved by the European Commission (EC) in early 2018 and launched in certain parts of Europe.

About CT-P10

CT-P10 was the world’s first monoclonal antibody (mAb) biosimilar approved by the European Commission (EC) for the treatment of oncology and launched in Europe in 2017. The reference product for CT-P10 is Rituxan® (rituximab)2. Rituxan® is used to treat patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). CT-P10 is currently pending FDA review and approval. The final U.S. prescribing information for CT-P10 will include the specific uses for which the product is indicated in the U.S. Rituximab, the active substance in CT-P10, has been designed to bind specifically to the transmembrane protein CD20 found on both malignant and normal B cells.

About Celltrion, Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. For more information, visit www.celltrion.com.

1 Herceptin® is a registered trademark of Genentech, Inc
2 Rituxan® is a registered trademark of Biogen and Genentech USA, Inc

Contact information

Celltrion, Inc.
Gunn Lee, +82 32 850 5168
Gunhyuk.lee@celltrion.com
or
Heewon Park, +82 32 850 5356
Heewon.park@celltrion.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The LYCRA Company Launches Annual Fall Denim Co-Marketing Program17.9.2019 09:00:00 CESTPress release

The LYCRA Company, owner of the LYCRA® brand family of fibers, announced today that it has launched a global co-branded marketing program to promote denim jeans made with its LYCRA® dualFX® technology. The marketing program will premiere on Refinery29, a leading global media and entertainment company for young women. Patented LYCRA® dualFX® technology combines two LYCRA® brand stretch fibers to add extra flexibility and bounce back recovery to denim. This means jeans hold their shape all day, every day resisting bag and sag while delivering exceptional comfort and fit. Inspired by the two fibers in LYCRA® dualFX® technology, diverse pairs of real women are featured in some of this year’s custom content campaign created by Refinery29. Whether it is a night on the town, on the dance floor or simply hanging out together, these women demonstrate how jeans with LYCRA® dualFX® technology deliver a comfortable, lasting fit for all body types regardless of their shape or size. The annual fall

Enapter Opens Serial Fabrication Facility for Modular Hydrogen Electrolysers17.9.2019 08:00:00 CESTPress release

Enapter, a manufacturer of modular hydrogen electrolysers, announced today the unveiling of its new serial fabrication facility in Pisa. The revamped manufacturing process will increase Enapter’s production capacity eightfold and reduce electrolyser costs by more than 20 percent. These improvements can make onsite hydrogen generation an affordable reality for a multitude of applications worldwide, including energy storage, backup power, power-to-heat, industrial hydrogen production and hydrogen-based mobility. Hydrogen generation has the potential to play a key role in the clean energy transition but has been limited by cost and scalability. Enapter’s EL 2.0 electrolyser addresses these challenges through its patented Anion Exchange Membrane (AEM) technology. With a simple balance of plant and no noble metals needed, Enapter’s AEM reduces costs and increases lifetime performance of hydrogen generation. Serial fabrication allows Enapter to deploy the current EL 2.0 hydrogen generator to

Seoul Semiconductor: Future Proof Human Centric Office-Lighting With SunLike is Already Here17.9.2019 08:00:00 CESTPress release

At Arlandastad in Stockholm, Sweden, the global technology supplier Schaeffler Group has its Nordic headquarters in a four-storey building being renovated in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005268/en/ SunLike luminaire made by LedLuks (Photo: Business Wire) The first floor to be opened after renovation shows carefully designed new lighting environments with the latest LED-technology, SunLike from Seoul Semiconductor. The ergonomically designed LED-luminaires are Plain Spectra from Annell, designed by well-renowned lighting designer Kai Piippo and produced by Ledluks. The lighting solution with the pleasant and healthy light was chosen by the architect for the project, VIRA Architects in Stockholm. Lighting designers were Lena Sjöström Larsson from VIRA Architects in cooperation with lighting supplier Annell. The result is called Human Centric Lighting. SunLike™ offers great possibilities, similar

New nCipher HSM as a Service Delivers High-Assurance Security for Organizations Adopting Cloud-First Strategies17.9.2019 07:01:00 CESTPress release

nCipher Security, an Entrust Datacard company, announces nShield as a Service, a cloud-based hardware security module (HSM) service that allows organizations to protect sensitive data and applications and helps meet compliance mandates – simply and efficiently, using on-demand cryptography. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005391/en/ How nCipher Security nShield as a Service works (Graphic: Business Wire) “Organizations embracing cloud-first strategies require cloud-first encryption,” said Peter Galvin, vice president of strategy, nCipher Security. “This means remote, automated management at scale, and flexible access control both in the cloud and onsite. nShield as a Service makes it easy to adopt a secure, multi-cloud encryption strategy using the same nShield HSMs organizations deploy onsite today.” nShield as a Service is ideal for cloud-first strategies, selective cloud migration, or adding HSM capac

Netsam boosts metro network capacity with ADVA technology17.9.2019 07:00:00 CESTPress release

ADVA (FSE: ADV) today announced that Netsam has deployed its FSP 3000 and FSP 150 to dramatically expand its metro network and answer fierce data demand. Featuring the ADVA FSP 3000 open line system (OLS) with micro-ROADMs and ADVA FSP 150 demarcation technology, the new solution gives the Swedish communication service provider (CSP) the power to quickly and easily turn up new high-value services. The flexible ROADM-based photonic layer ensures Netsam’s fiber resources are used with optimal efficiency. With this and the ADVA FSP 150 deployed at customer premises, Netsam is able to provide SLA-based business services with speeds up to 100Gbit/s. ADVA’s partner NetNordic, a leading solutions integrator in Scandinavia, also played a key role in the project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005130/en/ Netsam has deployed the FSP 3000 and FSP 150 to quickly and easily turn up new high-value services (Photo: Bu

Riversand Technologies Appoints New EVP to Lead Growth in Europe and Middle East17.9.2019 05:00:00 CESTPress release

Riversand Technologies, a leading software provider of Cloud-native SaaS Master Data Management (MDM) and Product Information Management (PIM), announces the appointment of Mr. Mikkel Jensen as executive vice president for Europe and the Middle East regions. Mikkel will be responsible for overseeing sales and revenue growth in Europe and the Middle East and managing these regions’ operations. He has more than 18 years of experience in Master Data Management. Previously, he held a variety of roles with increasing responsibility at Stibo Systems, including EVP, and VP of Product Strategy. “We are delighted to bring onboard a leader of the caliber of Mikkel with his depth and breadth of knowledge, to head Riversand’s European and Middle East regions,” says Upen Varanasi, founder and CEO at Riversand. Riversand has steadily increased its footprint in Europe over the past few years, successfully establishing itself as a Product Information Management leader serving top European brands acros